It Took 7 Miscarriages, 10 IVF cycles, 9 Years, and Nearly $200,000 to Solve My Fertility Issues
By Elizabeth Katkin,
Marie Claire
| 06. 15. 2018
After six miscarriages, six fresh in vitro fertilization (IVF) cycles, two frozen IVF cycles, and one healthy not yet two-year-old daughter, I was told by my New York–based fertility specialist and embryologist to give up on having another genetic child. I had just turned 40. Though I had spent nearly $200,000 on fertility treatments in the U.S. and the U.K.—a staggering sum—my previous two IVF cycles had produced precisely zero useable embryos. The seasoned professionals at my clinic in New York gently told me that it was time to face facts: I likely had no good eggs left. Experts I had seen over the previous eight years echoed their opinion.
Throughout the course of my fertility journey, I had been “blessed” with the ability to produce lots of eggs. The IVF cycle that brought us our daughter had been no different than its predecessors: twenty-eight eggs retrieved, seventeen fertilized, and thirteen mature embryos on the third day of their existence—science-speak for a reassuringly ample supply. But genetic testing revealed a startling result: only three of our embryos were chromosomally normal...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...